 Ezetimibe
"Ezetimibe" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
| Descriptor ID |
D000069438
|
| MeSH Number(s) |
D03.383.082.301.550
|
| Concept/Terms |
Ezetimibe- Ezetimibe
- (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
- Ezetimib
SCH 58235- SCH 58235
- 58235, SCH
- SCH-58235
- SCH58235
|
Below are MeSH descriptors whose meaning is more general than "Ezetimibe".
Below are MeSH descriptors whose meaning is more specific than "Ezetimibe".
This graph shows the total number of publications written about "Ezetimibe" by people in this website by year, and whether "Ezetimibe" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ezetimibe" by people in Profiles.
-
Kovach CP, Mesenbring EC, Gupta P, Glorioso TJ, Ho PM, Waldo SW, Schwartz GG. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease. JAMA Netw Open. 2023 08 01; 6(8):e2329066.
-
McQueen RB, Baum SJ, Louie MJ, Sasiela WJ, Bilitou A, Shah H, Nash B, Gillard KK, Ray KK. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. Am J Cardiovasc Drugs. 2023 Jan; 23(1):67-76.
-
Landmesser U, McGinniss J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Dilic M, Goodman SG, Jukema JW, Loy M, Pecin I, Pordy R, Poulsen SH, Szarek M, White HD, Schwartz GG. Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. Eur J Prev Cardiol. 2022 10 20; 29(14):1842-1851.
-
Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
-
Schwartz GG, Chaitman BR. Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should? J Am Coll Cardiol. 2019 11 19; 74(20):2463-2465.
-
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):3168-3209.
-
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines. J Am Coll Cardiol. 2019 06 25; 73(24):e285-e350.
-
Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.
-
Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Eckel RH, Cannon CP, Lee LV, Bessac L, Pordy R, Letierce A, Ray KK. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials. J Am Heart Assoc. 2018 09 18; 7(18):e009221.
-
Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|